AveXis
| Use attributes for filter ! | |
| Parent organizations | Novartis |
|---|---|
| Headquarters | Chicago |
| Illinois | |
| United States | |
| Founded | 2010 |
| Date of Reg. | |
| Date of Upd. | |
| ID | 1046114 |
About AveXis
AveXis is a biotechnology company that develops treatments for rare neurological genetic disorders. AveXis was acquired by Novartis in 2018. In 2019, Avexis won approval to market onasemnogene abeparvovec for spinal muscular atrophy.
